Guildford, UK: MedPharm Ltd (www.medpharm.com), the topical and transdermal formulation development specialist, today announced a new Formulation Fast Track Service enabling clients who are developing topical (skin, airways, ocular and muscosal) and transdermal formulations to begin manufacturing for clinical trials in just 4 months.

“We have added this service to help some of our clients who wish to progress their product into human trials as soon as possible, and take advantage of the early generation of clinical data. They can now do so with MedPharm’s new Formulation Fast Track Service, a specialist service to speed up the development of topical formulations and advance them to the clinic in as little as 4 months. By accepting inherent risks, our clients can take advantage of MedPharm’s expertise to quickly achieve the ultimate Proof of Concept for their formulation; a first in human clinical trial,” commented Dr. Andrew Muddle, CEO.

MedPharm is able to offer this specialised service by drawing on the company’s long history of formulation development experience to provide an accelerated formulation programme that produces a safe and stable, but ultimately non-optimised formulation, in just 4 months.  Clinical trial materials can also be manufactured on-site at MedPharm, enabling an efficient transition from development to manufacturing, with a rapid release to the clinical trial site. Following Proof of Concept studies, clients can then contract MedPharm to fully optimise and fine-tune their formulations.

Dr. Muddle continues, “This is just one of a multitude of services that our clients benefit from when they work with us. With a raft of topical and transdermal development, testing and manufacturing services, we are very well equipped, and experienced enough to satisfy even our clients’ most demanding formulation requirements”.


About the company:

MedPharm is a specialist pharmaceutical development company that is recognised internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) drug delivery systems and formulations. Established in 1999, and with numerous high profile customers, MedPharm has built a worldwide reputation for its unique and highly specialised service in contract research and development; together with expert project management. Projects range from simple feasibility tests, formulation and dosage form design and optimisation, through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed subsequent smooth transfer through to commercial manufacturing sites. The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical and transdermal drug delivery systems. These systems include MedSpray®, MedTherm® and AquaRMed™. It has produced these innovations by exploiting its internal product development expertise, with a particular focus on dermatology. The company is actively seeking to license these technologies to third parties for developing with their own compounds in non-competing indications. MedPharm’s laboratories in the UK are routinely inspected by Regulatory Authorities to ensure that its Quality System meets the requirements for GMP and GLP.

Back to News